Journal of Diabetes Research / 2012 / Article / Tab 1

Clinical Study

Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population

Table 1

Baseline data of patient characteristics in three groups.

End-stage PDRNormals ( )
Yes No

Male (n[%])62 (40.523)48 (39.024)63 (41.722)
Age, years#52.719 ± 6.661§57.626 ± 8.006*53.136 ± 7.342
PAI-1, pmol/dL#7.394 ± 2.0846.216 ± 0.989*1.952 ± 0.276
 95%CI7.062–7.7276.040–6.3931.851–2.053
Family history of DM (n[%])13 (8.497)§36 (29.268)
History of hypertension (n[%])89 (58.170)§75 (60.976)
Smoking (n[%])
 Active61 (39.869)46 (37.398)
 Passive153 (100.000)123 (100.000)
Duration of DM#12.496 ± 6.173§9.954 ± 4.441
FBG, mmol/L#7.125 ± 1.987§6.512 ± 2.157
PBG, mmol/L#9.919 ± 3.4019.226 ± 3.786
SBP, mmHg#136.272 ± 11.114§131.952 ± 14.719
DBP, mmHg#84.771 ± 6.985§82.602 ± 9.373
TC, mmol/L#5.161 ± 0.7845.222 ± 1.101
TG, mmol/L#2.115 ± 1.5091.854 ± 1.628
CREA, umol/L#82.971 ± 52.230§70.085 ± 33.491
BUN, mmol/L#6.890 ± 2.6306.345 ± 2.242
PAI-1, pmol/dL#7.394 ± 2.084§6.216 ± 0.989
WBC, 109/L#6.709 ± 1.6066.513 ± 1.953
RBC, 1012/L#4.350 ± 0.3964.347 ± 0.563
HGB, g/L#54.831 ± 65.599130.452 ± 18.130
Lymphocyte counts, 109/L#7.643 ± 2.164§1.784 ± 0.555
MPV, #9.871 ± 0.792§10.192 ± 0.971

* versus normals; § versus no end-stage PDR; versus normal.
#Continuous variables are presented as the mean with the standard deviation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.